Fulgent Genetics, Inc. FLGT Therapeutic Development — Indefinite Lived Intangible Assets Excluding Goodwill
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — indefinite lived intangible assets excluding goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s therapeutic development — indefinite lived intangible assets excluding goodwill?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — indefinite lived intangible assets excluding goodwill of $68.49M in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — indefinite lived intangible assets excluding goodwill changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — indefinite lived intangible assets excluding goodwill increased by 6.0% year-over-year, from $64.59M to $68.49M.
- What does therapeutic development — indefinite lived intangible assets excluding goodwill mean?
- Represents the value of intangible assets within the therapeutic development segment that are expected to provide cash flows indefinitely, such as certain trademarks or licenses. These assets are not amortized but are subject to annual impairment testing.